TIDMVENN

RNS Number : 2831E

Venn Life Sciences Holdings PLC

03 November 2015

3 November 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Grant of Share Option

& Total Voting Rights

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that it has granted an option over 770,000 ordinary shares, representing 1.28% of the current issued share capital of the Company, to Jonathan Hartshorn, Chief Financial Officer.

The shares have an exercise price of 23p, and an exercise period from 3 November 2018 to 2 November 2025.

Following this grant the Company has granted options over 3,640,000 ordinary representing 6.04% of the current issued share capital.

Total Voting Rights

The Company's issued share capital consists of 60,239,263 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that the total number of voting rights in the Company are 60,239,263.

Enquiries:

 
 Venn Life Sciences Holdings                           www.vennlifesciences.com 
  Plc 
 Tony Richardson, Chief Executive                          Tel: +353 154 99 341 
  Officer 
 Jonathan Hartshorn, Chief                                 Tel: +353 153 93 269 
  Financial Officer 
 Orla McGuinness, Marketing                                Tel: +353 153 93 269 
  Manager 
 
 Zeus Capital (Nominated Adviser 
  and Co-Broker) 
 Andrew Jones/Phil Walker                                    Tel: 0161 831 1512 
 Dominic Wilson/Alex Davies                                 Tel : 020 3829 5000 
 
 Hybridan LLP (Co-Broker) 
 Claire Louise Noyce                                         Tel: 020 3764 2341 
 
 Walbrook PR Ltd                      Tel: 020 7933 8787 or venn@walbrookpr.com 
 Paul McManus                                                Mob: 07980 541 893 
 Lianne Cawthorne                                            Mob: 07584 391 303

About Venn Life Sciences Limited:

Venn is a full service European Contract Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation, Venn specialises in both national and European-wide Phase II-Phase IV multi-site trials with extensive expertise in EU regulations, therapeutic areas and local languages. Over a 25 year history, Venn has built up substantial study experience, contributing to the efficient management of sites, budgets and communication channels with all parties involved. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. In October 2015 Venn completed the acquisition of Kinesis Pharma BV, highly differentiating Venn within the CRO market as it can now offer services from early clinical/non-clinical evaluation through to Phase IV. This deepens its service capability and enables Venn to offer a complete end-to-end service.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUUVNRVNAARAA

(END) Dow Jones Newswires

November 03, 2015 02:00 ET (07:00 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hvivo Charts.